Evaluation of serum dipeptidyl-peptidase-like protein 6 (dppx) levels in patients with epilepsy: a case…

Abstract

Objective: To compare serum DPPX levels between epilepsy patients and healthy controls, evaluate its diagnostic performance via ROC analysis, and assess associations with disease duration.

Methods: A hospital-based case-control study (Nov 2025–Mar 2026) included 50 epilepsy patients (18–75 years, both sexes, ≥1 year of aware/impaired awareness seizures) and 50 age-/sex-matched healthy controls. Exclusion criteria: diabetes, chronic diseases, autoimmune disorders, cancer, pregnancy, lactation. Serum DPPX measured by ELISA. Statistical analysis used SPSS v26 (t-test, chi-square, ROC). Significance: p≤0.05.

Results: Mean age was similar between patients (33.24±8.31 years) and controls (32.18±7.11 years; p=0.681). Serum DPPX was significantly lower in epilepsy patients (47.02±4.33 vs. 83.68±7.38 ng/mL; p=0.001). ROC analysis yielded an optimal cut-off <46.69 ng/mL (AUC=0.721, 95% CI: 0.623–0.819; p=0.001), sensitivity 70.0%, specificity 74.0%, PPV 72.9%, NPV 71.2%. No significant DPPX difference between disease duration ≤10 years (45.16±6.48 ng/mL) and >10 years (48.49±5.92 ng/mL; p=0.707).

Conclusion: Serum DPPX is significantly reduced in epilepsy patients, showing modest discriminatory value that remains stable across disease duration. It may serve as a potential adjunct biomarker. Larger prospective studies with epilepsy subtype stratification are warranted.

Elevated autoantibodies against dipeptidyl peptidase-4 are associated with poor prognosis in patients with type 2 diabetes
Takeshi Yagihashi, Takahide Hashimoto, Naoki Ohtake +9
Endocrine Journal22 Jul 2026Peer-reviewedCC BY-NC-NDFull textEndocrinology & metabolismJ-STAGE
Plant-Derived Dipeptidyl Peptidase-4 Inhibitors in Cardiometabolic Disorders: A Critical Review of Natural Scaffolds and Experimental Evidence
Kuanysh Zhapar, Diana Samatkyzy, Diana Valishayeva +3
Biomedicines22 Sep 2026Peer-reviewedCC BYFull textGeneral medicineEurope PMC
Sodium-glucose cotransporter 2 inhibitors vs. glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors for incident and recurrent urolithiasis: a European Association of Urology Endourology systematic review
Arianna Pischetola, Francesco Esperto, Arman Tsaturyan +4
Translational andrology and urology23 Sep 2026Peer-reviewedCC BY-NC-NDFull textGeneral medicineEurope PMC
Hepatic biomarker trajectories and mortality in septic adults with type 2 diabetes and recorded dipeptidyl peptidase-4 inhibitor exposure versus metformin-based therapy: A propensity-score-matched cohort study.
Aristomenis G Alevizopoulos, Georgios G Anastasiou, Paraskevas Nomikos +1
Metabolism open10 Oct 2026Peer-reviewedCC BYFull textEndocrinology & metabolismEurope PMC
Association of Glucagon-like Peptide-1 Receptor Agonists Versus Dipeptidyl Peptidase-4 Inhibitors with Tuberculosis and Mortality in Adults with Diabetes
Chun-Hsiang Hsu, Renin Chang, Chiu-Fan Chen +5
International Journal of Molecular Sciences1 Oct 2026Peer-reviewedCC BY 4.0Full textEndocrinology & metabolismCrossrefEurope PMC

Cite

BibTeX RIS

BibTeX

@article{hussein2026evaluation,
  title = {{Evaluation of serum dipeptidyl-peptidase-like protein 6 (dppx) levels in patients with epilepsy: a case control study from Al Diwaniyah governorate, Iraq}},
  author = {Ahmed Hussein and Salim Hassan},
  journal = {Babcock University Medical Journal},
  year = {2026},
  month = oct,
  doi = {10.38029/babcockuniv.med.j..v9is1.1581},
  url = {https://doi.org/10.38029/babcockuniv.med.j..v9is1.1581},
  note = {CC BY-NC},
}

RIS

TY  - JOUR
TI  - Evaluation of serum dipeptidyl-peptidase-like protein 6 (dppx) levels in patients with epilepsy: a case control study from Al Diwaniyah governorate, Iraq
AU  - Ahmed Hussein
AU  - Salim Hassan
PY  - 2026
DA  - 2026/10/01
JO  - Babcock University Medical Journal
DO  - 10.38029/babcockuniv.med.j..v9is1.1581
UR  - https://doi.org/10.38029/babcockuniv.med.j..v9is1.1581
AB  - Objective: To compare serum DPPX levels between epilepsy patients and healthy controls, evaluate its diagnostic performance via ROC analysis, and assess associations with disease duration.  Methods: A hospital-based case-control study (Nov 2025–Mar 2026) included 50 epilepsy patients (18–75 years, both sexes, ≥1 year of aware/impaired awareness seizures) and 50 age-/sex-matched healthy controls. Exclusion criteria: diabetes, chronic diseases, autoimmune disorders, cancer, pregnancy, lactation. Serum DPPX measured by ELISA. Statistical analysis used SPSS v26 (t-test, chi-square, ROC). Significance: p≤0.05.  Results: Mean age was similar between patients (33.24±8.31 years) and controls (32.18±7.11 years; p=0.681). Serum DPPX was significantly lower in epilepsy patients (47.02±4.33 vs. 83.68±7.38 ng/mL; p=0.001). ROC analysis yielded an optimal cut-off <46.69 ng/mL (AUC=0.721, 95% CI: 0.623–0.819; p=0.001), sensitivity 70.0%, specificity 74.0%, PPV 72.9%, NPV 71.2%. No significant DPPX difference between disease duration ≤10 years (45.16±6.48 ng/mL) and >10 years (48.49±5.92 ng/mL; p=0.707).  Conclusion: Serum DPPX is significantly reduced in epilepsy patients, showing modest discriminatory value that remains stable across disease duration. It may serve as a potential adjunct biomarker. Larger prospective studies with epilepsy subtype stratification are warranted.
SN  - 2465-6666
SN  - 2756-4657
ER  -

Abstract

Related

Cite